UnknownPhase 3

Role of Nefopam in Rituximab Transfusion Reaction

100 participantsStarted 2022-12-20

Plain-language summary

the patients will be taken nefopam ampule 50 mg before rituximab in the first group while the second group will be taken diphenhydramine ampule 10 mg before rituximab in the second group

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 - 80 years old male and female will be taken rituximab Exclusion Criteria: * less than 18 years old more than 80 years old diabetic patients

What they're measuring

transfusion reaction

Timeframe: 30 min

Trial details

NCT IDNCT05648058

SponsorMinistry Of Health / Nineveh Health Directorate

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2023-10-20

Contact for this trial

fakhraldin marwan

07817639470 drfakhralin@gmail.com

View on ClinicalTrials.gov More Nefopam trials